Page last updated: 2024-11-05

vigabatrin and Child Behavior Disorders

vigabatrin has been researched along with Child Behavior Disorders in 1 studies

Child Behavior Disorders: Disturbances considered to be pathological based on age and stage appropriateness, e.g., conduct disturbances and anaclitic depression. This concept does not include psychoneuroses, psychoses, or personality disorders with fixed patterns.

Research Excerpts

ExcerptRelevanceReference
"Vigabatrin (VGB) has demonstrated high efficacy in infantile spasms (IS) due to tuberous sclerosis."7.70Mental and behavioural outcome of infantile epilepsy treated by vigabatrin in tuberous sclerosis patients. ( Chiron, C; Dulac, O; Dumas, C; Jambaqué, I; Mumford, J, 2000)
"Vigabatrin (VGB) has demonstrated high efficacy in infantile spasms (IS) due to tuberous sclerosis."3.70Mental and behavioural outcome of infantile epilepsy treated by vigabatrin in tuberous sclerosis patients. ( Chiron, C; Dulac, O; Dumas, C; Jambaqué, I; Mumford, J, 2000)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Jambaqué, I1
Chiron, C1
Dumas, C1
Mumford, J1
Dulac, O1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Prednisolone vs. Vigabatrin in the First-line Treatment of Infantile Spasms[NCT02299115]Phase 30 participants (Actual)Interventional2017-09-05Withdrawn (stopped due to Most centres are now using oral steroids as 1st line treatment so question of efficacy is no longer of high interest.)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Other Studies

1 other study available for vigabatrin and Child Behavior Disorders

ArticleYear
Mental and behavioural outcome of infantile epilepsy treated by vigabatrin in tuberous sclerosis patients.
    Epilepsy research, 2000, Volume: 38, Issue:2-3

    Topics: Anticonvulsants; Autistic Disorder; Child Behavior Disorders; Cognition Disorders; Drug Therapy, Com

2000